The first epigenetic test to identify tumors of unknown primary

The EPICUP® test is a new tool that helps identify up to 87% of cases of cancer of unknown origin (CUP)

In patients with cancer, rx initial diagnosis most often includes the detection of the primary or original tumor and the presence or absence of metastases, ie cells from the original tumor that have escaped from their original location and are growing into other tissues of the patient. However, in between 5% and 10% of human tumors this process is done otherwise: metastasis is diagnosed, but the primary tumor is not detected despite various diagnostic testing. This situation is called Cancer of Unknown Primary (CUP). As the type of tumor is not known, the survival of these patients it is very limited.

Today, an article published in The Lancet Oncology, the most prestigious journal in the Medical Oncology field, by Dr. Manel Esteller, director of the Epigenetics and Cancer Biology Program (PEBC) of of Bellvitge Biomedical Research Institute (IDIBELL), ICREA researcher and Professor of Genetics at the University of Barcelona, shows that it is possible to use a newly-developed epigenetic test – called EPICUP®- to find out what type of primary tumor is responsible for the metastasis in the patient, which will allow doctors to develop more specific treatments against it.

Read Full Article Here >>